These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 14745691)

  • 1. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues.
    Karmali MA
    J Infect Dis; 2004 Feb; 189(3):355-9. PubMed ID: 14745691
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli.
    Paton JC; Rogers TJ; Morona R; Paton AW
    Infect Immun; 2001 Mar; 69(3):1389-93. PubMed ID: 11179303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.
    Watanabe M; Matsuoka K; Kita E; Igai K; Higashi N; Miyagawa A; Watanabe T; Yanoshita R; Samejima Y; Terunuma D; Natori Y; Nishikawa K
    J Infect Dis; 2004 Feb; 189(3):360-8. PubMed ID: 14745692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli.
    Nishikawa K
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):239-47. PubMed ID: 21644029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections.
    Serna A; Boedeker EC
    Curr Opin Gastroenterol; 2008 Jan; 24(1):38-47. PubMed ID: 18043231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome.
    Goldwater PN
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):653-63. PubMed ID: 17678428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli.
    Johnson KE; Thorpe CM; Sears CL
    Clin Infect Dis; 2006 Dec; 43(12):1587-95. PubMed ID: 17109294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Emerging infectious diseases--E coli O157 infections].
    Nagayama K; Kodama T; Honda T
    Nihon Naika Gakkai Zasshi; 1997 Nov; 86(11):2046-51. PubMed ID: 9480308
    [No Abstract]   [Full Text] [Related]  

  • 9. [Shiga toxin production by Escherichia coli strains and antibiotics].
    Sidorenko SV
    Antibiot Khimioter; 2001; 46(5):3-5. PubMed ID: 11558452
    [No Abstract]   [Full Text] [Related]  

  • 10. [Enterohemorrhagic Escherichia coli infection].
    Nakayama K; Sato T
    Nihon Rinsho; 2004 May; 62 Suppl 5():472-7. PubMed ID: 15197966
    [No Abstract]   [Full Text] [Related]  

  • 11. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites.
    Nelson JM; Griffin PM; Jones TF; Smith KE; Scallan E
    Clin Infect Dis; 2011 May; 52(9):1130-2. PubMed ID: 21467017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foodborne diseases: Shiga toxin producing E. coli (STEC).
    Bower JR
    Pediatr Infect Dis J; 1999 Oct; 18(10):909-10. PubMed ID: 10530589
    [No Abstract]   [Full Text] [Related]  

  • 14. Escherichia coli O157 in Somerset.
    Commun Dis Rep CDR Wkly; 1998 May; 8(19):167. PubMed ID: 9635338
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospects for the prevention of haemolytic-uraemic syndrome.
    Todd WT
    Lancet; 2001 May; 357(9269):1636-8. PubMed ID: 11425363
    [No Abstract]   [Full Text] [Related]  

  • 16. [New drugs that prevent cytotoxicity of Shiga toxins].
    Natori Y
    Nihon Rinsho; 2002 Jun; 60(6):1131-7. PubMed ID: 12078085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features of enterohemorrhagic E. coli gastrointestinal infection].
    Igarashi T
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():581-5. PubMed ID: 16523959
    [No Abstract]   [Full Text] [Related]  

  • 18. Virulence profiles of Shiga toxin 2e-producing Escherichia coli isolated from healthy pig at slaughter.
    Zweifel C; Schumacher S; Beutin L; Blanco J; Stephan R
    Vet Microbiol; 2006 Oct; 117(2-4):328-32. PubMed ID: 16872761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New approach for the absorbent therapy of verotoxin-producing Escherichia coli infection].
    Takeda T; Yoshino K; Matsuda E
    Nihon Rinsho; 1997 Mar; 55(3):751-7. PubMed ID: 9086793
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemolytic uremic syndrome: an emerging health risk.
    Razzaq S
    Am Fam Physician; 2006 Sep; 74(6):991-6. PubMed ID: 17002034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.